January is, and has been, Biotech month. With conferences in San Francisco wrapping up just in time for the AFC divisional playoff game this weekend, news flow will begin to hit the street of deals and JVA in the coming days and weeks. One penny stock many traders are speculating will have some positive momentum is that of Bio-Matrix Scientific Group Inc. (OTC: BMSN). Used by many seasoned traders as an ATM card of sorts, BMSN stock is a target of many to follow the path another break out biotech had from September whereby $500 would have yielded over $20,000 in the course of just 3 months.
Our Next Pick Is Coming Soon! Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
BMSN Stock Chart
Market Cap: 282.03K
Last: 0.0013 ▲ 0.0002 (18.18%)
Volume: 50,060,297
Dollar Volume: $52,934
Open: 0.0011
High: 0.0013
Low: 0.0009
Trades: 105
Authorized: 2,000,000,000
Issued and Outstanding: 1,035,911,549
14-Day Rel Strength: 58.56%
14-Day Stochastic: 50.00%
Looking for Hot Penny Stocks?
Click here To Receive FREE Penny Stock Alerts
As of 8AM Friday, Bio-Matrix Scientific Group is late in filing their 10-K which is surely why CEO, David Koos, felt it appropriate to issue the 8-K indicating the number of issued and outstanding shares as of December 31, 2012. Revenues will not be listed unless an agreement, which no one knows of, was made prior to the end of the year involving their wholly-owned subsidiary, Regen BioPharma, Inc.
In mid November, a safety and efficacy test of Regen’s HemaXellerate™ product using mice models for testing was said to begin by Cascade Life Sciences, Inc. Positive results from the test would have led to a safety profile data required for filing of an Investigational New Drug application for the product with the US Food and Drug Administration. The plan was for Regen BioPharma to file the application during Q4, 2012 with Phase I/II clinical trials expected to begin during 2013 and 2014 upon approval.
News or not, BMSN stock is a pure speculation play at present. For months, veteran penny stock traders have utilized the trading pattern as a sort of ATM card by swing trading it effectively. With new coverage beginning by the same groups who brought Amarantus BioScience, Inc. (AMBS) to the surface, the chances of a PR issuance about Regen BioPharma could crush the bid, sending BMSN past its 200 day moving average, 0.0038, or even to its 2012 summer levels of 0.062 even though less than half the number of shares were outstanding at that time.
About BMSN Stock
Bio-Matrix Scientific Group, Inc. is a development stage engaged primarily in the business of providing biospecimen depository services , namely offering cryopreservation of cellular specimens as well as laboratory processing of cellular specimens including stem cell banking. Click here to view the SEC filings for BMSN.
Last 5 Trading Sessions:
| Date | Last | Change | % Change | Volume |
| 01/10/13 | 0.0013 | +0.0002 | +18.18% | 50,060,297 |
| 01/09/13 | 0.0011 | -0.0001 | -8.33% | 30,973,600 |
| 01/08/13 | 0.0012 | unch | unch | 21,432,500 |
| 01/07/13 | 0.0012 | unch | unch | 109,784,695 |
| 01/04/13 | 0.0012 | -0.0002 | -14.29% | 108,174,602 |
Bottom Line: BMSN stock is worth a glance, or even a check-in, to see if the penny stock world is showing any love for it. With the huge number of shares which have been issued during the last 3 months, it’s going to take an enormous amount of bullishness to push BMSN stock above 0.005.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)
ShareJAN
